NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in CVS Health Corporation ("CVS" or the "Company") (NYSE: CVS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of CVS investors who were adversely affected by alleged securities fraud between May 3, 2023 and April 30, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/cvs-health-corporation-lawsuit-submis ...

The market expects CVS Health (CVS) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on August 7, 2024, might help the stock move higher if these key numbers are bette ...

NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of CVS Health Corporation (NYSE: CVS). Shareholders who purchased shares of CVS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/cvs-health-corporation-loss-submission-form-2/?id=92735&from=3 CLASS PERIOD: Ma ...

SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of CVS Health Corporation (NYSE: CVS) securities between May 3, 2023 and April 30, 2024, inclusive (the “Class Period”), have until September 10, 2024 to seek appointment as lead plaintiff of the CVS class action lawsuit. Captioned Nixon v. CVS Health Corporation, No. 24-cv-05303 (S.D.N.Y.), the CVS class action lawsuit charges CVS as well as certain of CVS’s top current and f ...

CVS Health Corporation (CVS) is scheduled to report second-quarter 2024 results on Aug 7, before the opening bell.In the last reported quarter, the company’s adjusted earnings of $1.31 missed the Zacks Consensus Estimate by 22.49%. CVS Health beat estimates in three of the trailing four quarters and missed in one, the average negative surprise being 2.25%.The Zacks Consensus Estimate for revenues is pegged at $91.56 billion, suggesting growth of 2.9% year over year. The consensus estimate for second-quarter ...

NEW YORK, July 29, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of CVS Health Corporation (NYSE: CVS).Shareholders who purchased shares of CVS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cvs-health-corporation-loss-submission-form-2/?id=92377&from=4CLASS PERIOD: May 3, 202 ...

Sometimes a beaten-down stock can present a valuable opportunity.While some stocks may trade at cheap valuations for very valid reasons, there's always more than share prices to consider when you're considering a business to add to your portfolio. When you invest in stocks for many years at a time, the list of companies you're willing to put capital into and hold for that long may narrow.Great companies don't suddenly become less so because the tide of investor sentiment shifts. Sometimes, quality businesse ...

文章核心观点 - CVS Health Corporation(CVS)被指控在2023年5月3日至2024年4月30日期间做出虚假和/或误导性陈述,并未披露以下信息[1][3][4]: 1) CVS用于确定计划保费的预测无法有效地考虑医疗成本趋势和医疗服务利用模式 2) 因此,CVS可能会产生大量费用来弥补未在预测中考虑的成本增加,这些成本并未包括在计划保费中 3) 因此,CVS夸大了其医疗保健福利分部的盈利能力 4) 与高管的保证相反,CVS其他主要分部的收入不足以抵消医疗保健福利分部支出增加的负面财务影响 根据相关目录分别进行总结 财务表现 - 2023年8月2日,CVS将其稀释每股收益(EPS)指引范围从6.90美元至7.12美元下调至6.53美元至6.75美元,并表示营业收入较上年同期下降30.7%,主要是由于医疗保健福利分部的下降[5] - 2024年2月7日,CVS将其稀释EPS指引范围从至少7.26美元下调至至少7.06美元,将其经调整EPS指引范围从至少8.50美元下调至至少8.30美元,将其营业活动产生的现金流指引从至少125亿美元下调至至少120亿美元[6] - 2024年5月1日,CVS报告收入884亿美元,低于预期的890亿美元,表示医疗服务利用率上升,即保险支出增加,以及Medicare报销率下降,将继续对CVS的业绩产生压力[7] 公司概况 - CVS是一家医疗保健公司[3] - Robbins Geller Rudman & Dowd LLP是一家全球领先的复杂集体诉讼公司,代表原告提起证券欺诈案件[8]

文章核心观点 Robbins Geller Rudman & Dowd LLP宣布CVS Health Corporation证券集体诉讼案，5月3日2023年至4月30日2024年期间购买该公司证券者可在9月10日2024日前申请成为首席原告，诉讼指控CVS及其高管违反1934年《证券交易法》 [1] 案件相关 诉讼指控 - 被告在集体诉讼期内作出虚假或误导性陈述，未披露CVS用于确定计划保费的预测无法有效反映医疗成本趋势和医疗保健使用模式 [2] - 因上述原因，CVS可能需承担未在预测中体现的成本增加费用，导致其医疗保健福利部门盈利能力被高估 [2] - 除医疗保健福利部门外，CVS其他主要部门收入不足以抵消该部门支出增加的负面影响 [2] 股价下跌情况 - 2023年8月2日，CVS将摊薄每股收益（EPS）指引区间从6.90 - 7.12美元下调至6.53 - 6.75美元，运营收入减少14亿美元（30.7%），消息公布后股价下跌 [3] - 2024年2月7日，CVS再次下调摊薄EPS、调整后EPS和运营现金流指引，消息公布后股价下跌 [3] - 2024年5月1日，CVS报告营收884亿美元，未达预期的890亿美元，消息公布后股价下跌近17% [4] 律所相关 律所简介 - Robbins Geller Rudman & Dowd LLP是全球领先的复杂集体诉讼律师事务所，过去十年中有六年在ISS证券集体诉讼服务律所排名中位居第一 [5] - 过去四年，该律所通过证券相关集体诉讼案为投资者追回66亿美元，比同期其他律所多22亿美元 [5] - 律所拥有200名律师，分布在10个办公室，曾获得多项重大证券集体诉讼赔偿，包括有史以来最大的72亿美元赔偿 [5] 联系方式 - 联系律师为J.C. Sanchez和Jennifer N. Caringal [1][6] - 联系电话为800 - 449 - 4900，邮箱为info@rgrdlaw.com [1][6] - 律所地址为655 W. Broadway, Suite 1900, San Diego, CA 92101 [6] - 申请首席原告相关信息可查看https://www.rgrdlaw.com/cases-cvs-health-corporation-class-acton-lawsuit-cvs.html [1] - 律所更多信息可查看https://www.rgrdlaw.com/services-litigation-securities-fraud.html [5]

Investors can contact the law firm at no cost to learn more about recovering their losses. LOS ANGELES, July 26, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises CVS Health Corporation ("CVS" or the "Company") (NYSE: CVS) investors who suffered substantial losses to contact Lesley Portnoy, Esq. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Po ...